title: Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced Parkinson model mice.
abstract: Nobiletin, a polymethoxylated flavonoid found in citrus fruit peel, reportedly improves memory impairment in rodent models. Here we report its effect on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced motor and cognitive deficits. Nobiletin administration (50mg/kg i.p.) for 2 consecutive weeks improved motor deficits seen in MPTP-induced Parkinson model mice by 2weeks, an effect that continued until 2weeks after drug withdrawal. Drug treatment promoted similar rescue of MPTP-induced cognitive impairment at equivalent time points. Nonetheless, nobiletin treatment did not block loss of dopaminergic neurons seen in the MPTP-treated mouse midbrain, nor did it rescue decreased tyrosine hydroxylase (TH) protein levels seen in the striatum or hippocampal CA1 region of these mice. Interestingly, nobiletin administration (50mg/kg i.p.) rescued reduced levels of Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) autophosphorylation and phosphorylation at Thr-34 of dopamine- and cAMP-regulated phosphoprotein-32 (DARPP-32) in striatum and hippocampal CA1 to levels seen in sham-operated mice. Likewise, CaMKII- and cAMP kinase-dependent TH phosphorylation was significantly restored by nobiletin treatment. MPTP-induced reduction of dopamine contents in the striatum and hippocampal CA1 region was improved by nobiletin administration (50mg/kg i.p.). Acute intraperitoneal administration of nobiletin also enhanced dopamine release in striatum and hippocampal CA1, an effect partially inhibited by treatment with nifedipine (a L-type Ca(2+) channel inhibitor) or NNC 55-0396 (a T-type Ca(2+) channel inhibitor) and completely abolished by combined treatment with both. Overall, our study describes a novel nobiletin activity in brain and suggests that nobiletin rescues motor and cognitive dysfunction in MPTP-induced Parkinson model mice, in part by enhancing dopamine release.
authors: Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
authors: Y
authors: Y
authors: Yabuki
authors: School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan; Department of Anti-dementia Functional Food Development, Graduate School of Engineering, Tohoku University, Sendai, Japan; Laboratory of Kampo Medicines, Yokohama College of Pharmacy, Yokohama, Japan; Kasei Fukushi Research Center, Tohoku Fukushi University, Sendai, Japan.
authors: Y
authors: Y
authors: Ohizumi
authors: Laboratory of Medicinal Plant Science, School of Pharmacy, Tokyo University of Pharmacy and Life Science, Tokyo, Japan.
authors: A
authors: A
authors: Yokosuka
authors: Laboratory of Medicinal Plant Science, School of Pharmacy, Tokyo University of Pharmacy and Life Science, Tokyo, Japan.
authors: Y
authors: Y
authors: Mimaki
authors: Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan. Electronic address: kfukunaga@m.tohoku.ac.jp.
authors: K
authors: K
authors: Fukunaga
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D001362:Avoidance Learning / Q000187:drug effects; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D002121:Calcium Channel Blockers / Q000494:pharmacology; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology*; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005106:Exploratory Behavior / Q000187:drug effects; D047309:Flavones / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009043:Motor Activity / Q000187:drug effects*; D009419:Nerve Tissue Proteins / Q000378:metabolism; D020734:Parkinsonian Disorders / Q000150:complications* / Q000473:pathology; D011597:Psychomotor Performance / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
chemical_list: D000975:Antioxidants; D002121:Calcium Channel Blockers; D047309:Flavones; D009419:Nerve Tissue Proteins; C008661:nobiletin; D004298:Dopamine
keywords: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; ANOVA; CREB; Ca(2+)/calmodulin-dependent protein kinase II; CaMKII; DAB; DARPP-32; ECD; ERK; HPLC; LTP; MPTP; PBS; PD; PDE; PET; PKA; PKC; Parkinson’s disease; SN; SNpc; TH; VDCCs; VTA; Voltage-dependent Ca(2+) channel; analysis of variance; cAMP-dependent protein kinase; cognitive function; cyclic-AMP-responsive-element-binding protein; diaminobenzidine; dopamine- and cAMP-regulated phosphoprotein-32; electrochemical detector; extracellular signal-regulated kinase; high-performance liquid chromatography; long-term potentiation; nobiletin; phosphate-buffered saline; phosphodiesterase; positron emission tomography; protein kinase C; substantia nigra; substantia nigra pars compacta; tyrosine hydroxylase; ventral tegmental area; voltage-dependent Ca(2+) channels